nkf-pharma

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF-Pharma) is a publicly traded biopharmaceutical company headquartered in Nanjing, China, specializing in the research, development, production, and sale of heparin-related products and high-end sterile injectables. Founded on October 16, 2000, the company has established itself as a significant player in the global pharmaceutical market, particularly in the heparin value chain. The company's leadership includes Chairman Zu Qing Liu and CEO Yong Qun Tang.

NKF-Pharma's core business revolves around its sterile injection segment, heparin active pharmaceutical ingredient (API) business, and a growing Contract Development and Manufacturing Organization (CDMO) service line. The company manufactures and markets a range of products including standard heparin raw materials, low molecular weight heparin (LMWH) raw materials, and their subsequent preparations. Key products in its portfolio are Enoxaparin Sodium injection, Dalteparin Sodium injection, and Nadroparin Calcium injection, which are critical anticoagulants used to prevent and treat thrombosis. The company has expanded its offerings to include treatments in oncology and critical care, with products like Bortezomib, Eptifibatide, and various anti-tumor injectables.

The company operates on a global scale, with a strong focus on exporting its products to the United States and European countries. It has successfully built an internationalization platform, becoming one of the largest suppliers of high-end injectables to the U.S. market, securing numerous Abbreviated New Drug Application (ANDA) approvals from the U.S. Food and Drug Administration (FDA) annually. This is supported by its manufacturing sites, which are accredited by international regulatory bodies including the USFDA and the European Medicines Agency (EMA). Revenue is generated through the direct sale of its APIs and finished dosage forms to a customer base that includes major pharmaceutical companies, as well as through its CDMO services for small molecules, macromolecules, and cell and gene therapies.

NKF-Pharma went public on the Shanghai Stock Exchange on July 19, 2017. The firm has engaged in strategic collaborations, such as a 2014 partnership with ScinoPharm Taiwan to jointly develop and commercialize the new drug Regadenoson for the Chinese market. This move illustrates the company's strategy to transition from generic APIs to developing new drugs, enhancing its long-term competitiveness. For the first quarter of 2024, the company reported sales of CNY 1,004.27 million. Keywords: heparin API, low molecular weight heparin, sterile injectables, pharmaceutical manufacturing, anticoagulant, Enoxaparin Sodium, Dalteparin Sodium, biopharmaceutical, CDMO services, drug delivery, USFDA approved, generic drugs, thrombosis treatment, pharmaceutical exports, Nanjing, injectable preparations, active pharmaceutical ingredients, oncology injectables, biosimilars, pharmaceutical development